Let's Win Pancreatic Cancer

Learn more about daraxonrasib, other drugs targeting KRAS, and vaccines by watching our webinar. At our July 8th webinar, in partnership with the Nuestras Voces Adelante program of the National Alliance for Hispanic Health, we focused on the latest treatments. Dr. Gulam Manji and Dr. Allyson Ocean provided updates on the ones that have been in the national news and ones that have made waves in the pancreatic cancer community.

Acute pancreatitis led to diagnosis Survived breast cancer 10 years before diagnosis Whipple surgery and chemo during COVID-19 Other survivors gave me hope Serving as a patient advocate In the fall of 2020, during the height of COVID-19, I realized I was overdue for a physical exam. I had casually mentioned to friends that my stomach felt “off,” but I had acid reflux and attributed my symptoms to just that. It was nothing dramatic.

Let’s Win turned 10 in May. A lot has changed since we launched in 2016. Newer treatments such as NALIRIFOX and stereotactic body radiation therapy are now offered. Genetic testing has now become standard of care, to help patients with certain mutations access the best treatments for them. Molecular profiling is on the rise, as identifying tumor mutations becomes important for both clinical trials and treatments. The survival rate has increased from 8 percent to 13 percent but that is still very low.

University of Michigan School for Environment and Sustainability; Flickr The 2026 American Society of Clinical Oncology (ASCO) annual meeting was a notable one for pancreatic cancer research.

20 years of stomach pain eventually led to diagnosis Softball-sized tumor Microsatellite instability informs treatment Chemotherapy plus immunotherapy For at least twenty years, my stomach was bloated and irritated. Eating just about any kind of food gave me diarrhea, pain, and cramps. My doctors tested me for everything—IBS, Crohn’s disease, etc. All they came up with was that I was intolerant of certain foods. By 2021, I was in so much misery that I needed more answers.

Matthew Rosenblum was diagnosed with stage IV pancreatic cancer at 33; he did not expect to make it to 38. Thanks to treatments that targeted his BRCA mutation, a successful Whipple procedure, and support from friends and family, he is cancer free. The icing on the cake? The man who once thought it impossible to have a career and a family happily now has both. Read more about Matthew in “Sometimes Things Get Worse Before They Get Better.” Share Your Story. Help others by sharing your experiences.

Let’s Win reached its 10th anniversary this spring. We asked the members of our Patient Advisory Board to look back at the changes they have seen in the last 10 years, and what they wish to see in the future. No two responses were the same, and we will be sharing those in the coming weeks. We are launching this series with a personal reflection from Roberta Luna, a 24-year survivor.

Once considered undruggable, KRAS research has exploded, with scientists developing and testing drugs that target specific variants of the oncogene. Until recently there were no KRAS inhibitors available to patients outside of a clinical trial. That changed in May 2026, when the FDA authorized expanded access for daraxonrasib (RMC-6236), Revolution Medicines’ investigational pan-RAS inhibitor.

David Kashatus; National Cancer Institute / Univ. of Virginia Cancer Center There was a well-deserved standing ovation after Revolution Medicines presented final data on the RASolute 302 clinical trial. The report was a premier event at the 2026 ASCO Annual Meeting, held in Chicago from May 29 to June 2. The trial tested the KRAS inhibitor daraxonrasib as a second-line treatment for metastatic pancreatic cancer.

When a pancreatic cancer diagnosis enters the equation, roles and routines can shift dramatically—no matter how solid your relationship. A spouse becomes a caregiver. A child becomes an advocate.